Xuelin Huang, Ph.D.
Department of Biostatistics, Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Dr. Mien-Chie Hung and Mrs. Kinglan Hung Endowed Professor, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Deputy Chair, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Member, Quantitative Sciences, University of Texas Graduate School of Biomedical Science, Houston, TX
Adjunct Professor, Biostatistics, University of Texas Health Science Center at Houston, Houston, TX
Adjunct Professor, Biostatistics, Rice University, Houston
Professor, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Member, Quantitative Sciences, University of Texas Graduate School of Biomedical Science, Houston, TX
Adjunct Professor, Biostatistics, University of Texas Health Science Center at Houston, Houston, TX
Adjunct Professor, Biostatistics, Rice University, Houston
Professor, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2002 | University of Michigan, Ann Arbor, Michigan, US, Biostatistics, Ph.D |
| 1997 | Texas A & M University, College Station, Texas, US, Mathematics, M.S |
| 1994 | Peking University, Beijing, CN, Probability & Statistics, BS |
Licenses & Certifications
| 2026 | UT MD Anderson Institutional AI 101 Training |
Experience & Service
Faculty Academic Appointments
Associate Professor, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2013
Assistant Professor, Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2002 - 2007
Research Assistant, Department of Biostatistics, University of Michigan, Ann Arbor, MI, 2000 - 2002
Graduate Assistant, Department of Mathematics, Texas A & M University, College Station, TX, 1995 - 1997
Extramural Institutional Committee Activities
Member, Clinical Research Committee (CRC1), The University of Texas MD Anderson Cancer Center, 2018 - Present
member, Faculty Academic Review Committee (FARC), The University of Texas MD Anderson Cancer Center, 2015 - 2018
Member, GSBS Curriculum Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2015
Member, Clinical Research Committee (CRC4), The University of Texas MD Anderson Cancer Center, 2011 - 2014
Member, Institutional Animal Care and Use Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2009
Editorial Activities
Associate Editor, Journal of the Royal Statistical Society, Series C, 2019 - 2023
Associate Editor, Statistics in BioSciences, 2017 - Present
Associate Editor, Biometrics, 2016 - 2018
Member of Editorial Review Board, Journal of Clinical Oncology, 2011 - 2013
Honors & Awards
| 2017 - Present | Fellow, American Statistical Association |
| 2002 | Rackham Graduate School Travel Grant, University of Michigan |
| 2001 | Best Student Paper Award, Biopharmaceutical Section of the American Statistical Association |
| 1999 | National Science Foundation Traveling Grant, NSF/CBMS Regional Conference in Statistical Inference in Genetic Data |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2025. Individual Dynamic Prediction for Cure and Survival Based on Longitudinal Biomarkers. Invited. Lifetime Data Science. New York City, New York, US.
- 2020. Conditional Generative Adversarial Networks for Individualized Treatment Effect Estimation and Treatment Selection. Invited. ICSA. Houston, TX, US.
- 2018. Optimal Timing of Stem Cell Transplant for Leukemia Patients. Invited. ENAR. Atlanta, GA, US.
- 2017. Using Longitudinal Biomarker Data to Dynamically Predict Time to Disease Progression. Invited. Joint Statistical Meeting. Baltimore, MD, US.
- 2017. Using Longitudinal Biomarker Data to Dynamically Predict Time to Disease Progression. Invited. Conference on Lifetime Data Science, University of Connecticut. Storrs, CT, US.
- 2017. Using Longitudinal Biomarker Data to Dynamically Predict Time to Disease Progression. Invited. ENAR. Washington, DC, US.
- 2016. Functional Data Analysis Approach for Using Longitudinal Biomarker to Predict Disease Progression. Invited. Joint Statistical Meeting. Chicago, TX, US.
International Presentations
- 2025. Flexible hazards and cure models for dynamic prediction based on longitudinal biomarker measurements. Invited. The 19th International Joint Conference on Computational and Financial Econometrics and Computational and Methodological Statistics. London, GB.
- 2025. Individual Treatment Decision-Making and Dynamic Prediction for Cure and Survival Based on Longitudinal Biomarker Measurements. Invited. Western North American Region. Whistler, CA.
- 2024. Empirical Bayesian Approach for Response Adaptive Clinical Trial Design. Invited. The Eastern Asia Chapter of ISBA. Hong Kong, HK.
- 2023. Dynamic prediction of disease progression for cancer patients by functional principal component analysis (FPCA) of high dimensional longitudinal expression levels of oncogenes. Conference. Joint Statistical Meeting. Toronto, CA.
- 2023. Bayesian Models Connecting Short-Term Response with Long-Term Survival for Efficient Outcome-Adaptive Randomization in Oncology Clinical Trials. Invited. International Society of Bayesian Analysis-Eastern Asia Chapter. Qingdao, CN.
- 2017. Comparison of different approaches for dynamic prediction of survival using longitudinal biomarker data. Invited. International Chinese Statistical Association (ICSA) Applied Statistics Symposium. Chicago, US.
- 2016. Using Longitudinal Biomarker Data to Dynamically Predict Time to Disease Progression. Invited. The 10th International Chinese Statistical Association (ICSA) International Conference on Global Growth of Modern Statistics in the 21st Century, CN.
- 2016. Dynamic Prediction of Time-to-Event Distributions. Invited. The International Biometrics Society. Austin, US.
Formal Peers
- 2022. Innovative Phase II and III Oncology Clinical Trial Designs, US.
- 2021. From p-Value to q-Value, US.
- 2021. Innovative Statistical Methods for Clinical Trials, Observational Studies and Bioassays, US.
- 2020. Innovative Phase II Oncology Clinical Trial Designs. Invited. New York, NY, US.
- 2018. Multi-State Models Joint with Functional Principal Component Analysis for Longitudinal Data. Invited. West Lafayette, IN, US.
- 2017. Using Longitudinal Biomarker Data to Dynamically Predict Time to Next Failure Event. Invited. Houston, TX, US.
- 2017. Using Longitudinal Biomarker Data to Dynamically Predict Time to Next Failure Event. Invited. Baltimore, MD, US.
- 2017. Connecting Short-Term Response with Long-Term Survival for Efficient Outcome-Adaptive Randomization in Oncology Clinical Trials. Invited. Baltimore, MD, US.
- 2016. Using Longitudinal Biomarker Data to Dynamically Predict Time to Disease Progression. Invited. Houston, TX, US.
- 2012. Dynamic Prediction Models for Cancer Patient Disease Progression and Survival. Invited. Rochester, NY, US.
- 2011. Using Information on Both Short-Term Response and Long-Term Survival in the Design of Oncology Clinical Trials. Invited. Tempe, AZ, US.
- 2009. Using Short-Term Response to Facilitate Adaptive Randomization for Survival Clinical Trials. Invited. Houston, TX, US.
- 2007. Proportional Hazards Model with an Assumed copula for Dependent Censoring: A Sensitivity Analysis Approach. Invited. Cleveland, OH, US.
- 2006. Proportional Hazards Model with a Summed Copula for Dependent Censoring: A Sensitivity Analysis Approach. Invited. Portland, OR, US.
- 2006. Proportional Hazards Model with an Assumed copula for Dependent Censoring: A Sensitivity Analysis Approach. Invited. Portland, OR, US.
- 2006. A Parallel Phase I/II Clinical Trial Design for Combination Therapies. Invited. Charlottesville, VA, US.
- 2005. Optimization of Multi-Stage Treatment Sequences for Recurrent Diseases. Invited. Pittsburgh, PA, US.
- 2004. Estimation of the Effects of Treatment Sequences on Survival. Invited. Madison, WI, US.
- 2002. The Analysis of Correlated Survival Data with Dependent Censoring. Invited. St. Louis, MO, US.
- 2002. The Analysis of Correlated Survival Data with Dependent Censoring. Invited. Gainesville, FL, US.
- 2002. The Analysis of Correlated Survival Data with Dependent Censoring. Invited. Arcadia, CA, US.
- 2002. The Analysis of Correlated Survival Data with Dependent Censoring. Invited. Charleston, SC, US.
- 2002. The Analysis of Correlated Survival Data with Dependent Censoring. Invited. Kansas City, KS, US.
- 2002. The Analysis of Correlated Survival Data with Dependent Censoring. Invited. Indianapolis, IN, US.
- 2002. The Analysis of Correlated Survival Data with Dependent Censoring. Invited. Providence, RI, US.
- 2002. The Analysis of Correlated Survival Data with Dependent Censoring. Invited. Memphis, TN, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Collaborative Modeling to Identify Strategies to Improve the US Breast Cancer Outcomes in an Era of Innovation |
| Funding Source: | SUBAWARD VIA UNIVERSITY OF WISCONSIN MADISON |
| Role: | PI |
| ID: | 1 U01 CA319080-01 |
| Date: | 2026 - 2027 |
| Title: | TOPAz- Project 1: 2022-0880 Trial Of PreoperAtive Radiation |
| Funding Source: | ARTIDIS AG |
| Role: | Key |
| ID: | RCTS#61817 |
| Date: | 2026 - 2027 |
| Title: | EMPOwER - Project 2: 2023-0320 |
| Funding Source: | ARTIDIS AG |
| Role: | Key |
| ID: | RCTS#62744 |
| Date: | 2025 - 2026 |
| Title: | Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| ID: | AWD00001821 |
| Date: | 2025 - 2026 |
| Title: | Comparative Modeling of Precision Breast Cancer Control Across the Translational Continuum |
| Funding Source: | NIH/NCI subaward via University of Wisconsin Madison |
| Role: | PI |
| ID: | U01CA253911-S1 |
| Date: | 2025 - 2030 |
| Title: | Developing novel targeted therapies for Advanced Myeloproliferative Neoplasms |
| Funding Source: | NATIONAL CANCER INSTITUTE |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | High-dimensional Mediation Analysis of Cardiovascular Traits with Multi-omics Data |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21HL170213-01A1 |
| Date: | 2023 - 2027 |
| Title: | Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individual |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA272806-01A1 |
| Date: | 2022 - 2026 |
| Title: | Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individual |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA272806-01 |
| Date: | 2021 - 2024 |
| Title: | Collaborative Research: Individually tailored hierarchical Bayesian models for longitudinal biomarker monitoring and prediction of disease progression |
| Funding Source: | National Science Foundation (NSF) |
| Role: | PI |
| ID: | 2113716 |
| Date: | 2020 - 2025 |
| Title: | Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA255960-01 |
| Date: | 2020 - 2025 |
| Title: | Comparison of Survival Time for Leukemia Patients under Different Treatment Options |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA251688-01 |
| Date: | 2020 - 2024 |
| Title: | Evidence-Based Continuous Monitoring and Early Prediction of Progression for Chronic Diseases |
| Funding Source: | National Science Foundation (NSF) |
| Role: | PI |
| ID: | 1953737 |
| Date: | 2019 - 2022 |
| Title: | Optimal Personalized Treatment Decisions by Multi-State Models Joint with Functional Principal Component Analyses for Longitudinal Biomarker Data |
| Funding Source: | National Science Foundation (NSF) |
| Role: | PI |
| ID: | FP00007058 |
| Date: | 2019 - 2026 |
| Title: | Cancer Center Support Grant (CCSG) - Biostatistics Resource Group (BRG) |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| ID: | 5P30CA016672-47 |
| Date: | 2019 - 2023 |
| Title: | Optimal Stage and Timing for Leukemia Patients to Receive Stem Cell Transplants |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA234032-01A1 |
| Date: | 2018 - 2023 |
| Title: | Optimal Stage and Timing for Leukemia Patients to Receive Stem Cell Transplants |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA234032-01 |
| Date: | 2017 - 2022 |
| Title: | Integrating Multiple Data Sources to Examine the Generalizability of Treatment Effects on Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R01 CA221977-01 |
| Date: | 2016 - 2019 |
| Title: | Dynamic Prediction of Time to Next Failure Event |
| Funding Source: | National Science Foundation (NSF) |
| Role: | PI |
| ID: | DMS-1612965/PD08-1269 |
| Date: | 2016 - 2020 |
| Title: | Statistical methods to Improve Early Cancer Detection by Longitudinal Biomarkers |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA197861-01A1 |
| Date: | 2015 - 2020 |
| Title: | Statistical Methods to Improve Early Cancer Detection by Longitudinal Biomarkers |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA197861-01 |
| Date: | 2013 - 2015 |
| Title: | Statistical methods for optimizing multi-stage cancer treatments |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R21 CA176508 01 |
| Date: | 2012 - 2015 |
| Title: | Optimal personalized dynamic treatment regimes for recurrent diseases |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP130021 |
| Date: | 2012 - 2017 |
| Title: | Optimal personalized dynamic treatment regimes for recurrent diseases |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R01 CA163717 01A1 |
| Date: | 2012 - 2014 |
| Title: | A new analytic approach to optimal personalized treatments for recurrent diseases |
| Funding Source: | Patient-Centered Outcomes Research Institute (PCORI) |
| Role: | PI |
| ID: | Coeus #3507 |
| Date: | 2007 - 2009 |
| Title: | Joint Statistical Models for Leukemia and Treated-Related Outcomes |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R21 CA131757 01 |
| Date: | 2007 - 2009 |
| Title: | Statistical Models for Leukemia and NonLeukemia Outcomes |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R21 CA131757 01 |
Selected Publications
Peer-Reviewed Articles
- Huang X, Valero¹ V, Pohlmann¹ PR, Mouabbi¹ J, Huang² X, Qiao² W, Alonzo¹ H, Murthy¹ RK, Rauch³ GM, Adesoye⁴ T, Checka⁴ C, Symmans⁵ FW, Grachev⁶ D, Alajajyan⁶ F, Nwosu-Iheme A, Hassan A, Patel M, Giordano¹ SH, Hunt⁴ K, Tripathy¹ D, Meric-Bernstam⁴ F. Zanidatamab in Patients with Early Stage HER2-positive Breast Cancer: The NeoZanHER Phase 2 Single-Arm Open-Label Trial. Nature Communications, 2026.
- Xie C, Li R, Saber W, Cortes JE, Short NJ, Huang X. Toolkit for Multistate Disease Progression Simulation and Treatment Decision-Making Aid. BMC Medical Research Methodology, 2026. e-Pub 2026.
- Xie C, Li R, Morris JS, Short NJ, Kantarjian HM, Huang X. A functional landmark flexible-hazards cure model for individual dynamic prediction. Annals of Applied Statistics, 2026. e-Pub 2026.
- Short NJ, Bataller A, DiNardo CD, Montalban-Bravo G, Wang SA, Wang W, Maiti A, Nguyen D, Hachem MC, Bi TM, Issa GC, Chien KS, Ohanian M, Kadia TM, Loghavi S, Karrar O, Bachireddy P, Hwang H, Huang X, Garcia-Manero G, Ravandi F. Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study. Journal of Hematology and Oncology, 2026. e-Pub 2026. PMID: 42365365.
- Kantarjian, HM, Qiao, W, Jain, N, Jen, WY, Kugler, E, Short, NJ, Garris, R, Pierce, S, Kebriaei, P, Wang, SA, Haddad, FG, Ravandi-Kashani, F, Huang, X, Jabbour, EJ. Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemia. Cancer 132(8):70401, 2026. e-Pub 2026. PMID: 41954167.
- Croden J, Garcia-Manero G, Chien K, DiNardo C, Borthakur G, Hammond D, Bose P, Short N, Romero L, Shneider H, Hatfield M, Pierce S, Huang X, Hwang H, Montalban-Bravo G. A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia & Lymphoma, 2026. e-Pub 2026.
- Chi S, Li X, Wei P, Huang X. MELODY: Mediation Analysis in Logistic Regression for High-Dimensional Mediators and a Binary Outcome. Genetic Epidemiology 50(1):70033, 2026. e-Pub 2026.
- Short, NJ, Kantarjian, HM, Jain, N, Kadia, TM, Senapati, J, Haddad, FG, Maroun, MM, Sasaki, K, Xiao, L, Huang, X, Karrar, OS, Abramova, R, Zhao, M, Garris, R, Konopleva, M, Ravandi-Kashani, F, Jabbour, EJ. Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia. Blood Advances 10(1):25-28, 2026. e-Pub 2026. PMID: 40763277.
- Kropf P, Chung W, Shameem R, Xiao L, Balc, C, Huang X, Issa JP. A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML. Blood Neoplasia 2(2):100071, 2025. e-Pub 2025. PMID: 40453133.
- Li Y, Lai D, Li R, Chen H, Huang X, Ning J. A Biomarker Signature-Guided Clinical Trial Design for Precision Medicine. Statistics in Medicine 44(10-12):70103, 2025. e-Pub 2025. PMID: 40405471.
- Xie C, Huang X, Li R, Shen Y, Short NJ, Bhalla K. A new cure model accounting for longitudinal data and flexible patterns of hazard ratios over time. Statistical Methods in Medical Research 34(4):683-700, 2025. e-Pub 2025. PMID: 40017371.
- Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, Kanagal-Shamanna R, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Garris R, Nasnas C, Nasr L, Ravandi F, Jabbour E. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol 42(36):JCO2400272, 2024. e-Pub 2024. PMID: 39028925.
- Chien KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, Hammond DE, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Dong XQ, Pierce S, Huang X, Jabbour EJ, Kantarjian H, Garcia-Manero G. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leukemia Research 147:107602, 2024. e-Pub 2024. PMID: 39461095.
- Rodriguez-Sevilla JJ, Ademà Llobet V, Chien KS, Loghavi S, Ma F, Yang H, Montalban-Bravo G, Huang X, Calvo X, Joseph J, Bodden K, Garcia-Manero G, Colla S. The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial. Nature communications 15(1):9840, 2024. e-Pub 2024. PMID: 39537648.
- Xie C, Huang X, Li R, Tsodikov A, Bhalla K. Individual Dynamic Prediction for Cure and Survival Based on Longitudinal Biomarkers. Annals of Applied Statistics 18(4):2796-2817, 2024. e-Pub 2024.
- Ravandi, F, Senapati, J, Jain, N, Short, NJ, Kadia, TM, Borthakur, G, Konopleva, M, Wierda, WG, Huang, X, Maiti, A, Issa, GC, Balkin, H, Garris, R, Ferrajoli, A, Garcia-Manero, G, Alvarado, Y, Kebriaei, P, Jabbour, EJ, Kantarjian, HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 38(12):2717-2721, 2024. e-Pub 2024. PMID: 39322712.
- Short, NJ, Nguyen, D, Jabbour, EJ, Senapati, J, Zeng, Z, Issa, GC, Abbas, HA, Nasnas, C, Qiao, W, Huang, X, Borthakur, G, Chien, KS, Haddad, FG, Pemmaraju, N, Karrar, OS, Nguyen, D, Konopleva, M, Kantarjian, HM, Ravandi, F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia. The Lancet Haematology 11(11):e839-e849, 2024. e-Pub 2024. PMID: 39303729.
- Kim E, Chen SS, Sivina M, Hwang H, Huang X, Ferrajoli A, Jain N, Wierda WG, Wodarz D, Chiorazzi N, Burger JA. Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD. Blood 144(25):2678-2681, 2024. e-Pub 2024. PMID: 39441901.
- Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Pemmaraju N, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal R, Pierce S, Meyer M, Huang X, Garcia-Manero G. A Phase II Trial of Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab With or Without Azacitidine in Relapsed or Refractory Myelodysplastic neoplasms. Leukemia 39(2):524-528, 2024. e-Pub 2024. PMID: 39551874.
- Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein L, Welm A, Dean DA, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm B, Govinden R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona L, Herylyn M, Davies MA, Shapiro GI, Fields R, Trevino JG, Harrell JC, Consortium NCI, Doroshow JH, Chuang JH, Moscow JA. Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther 23(7):924-938, 2024. e-Pub 2024. PMID: 38641411.
- Montalban-Bravo G, Jabbour E, Chien K, Hammond D, Short N, Ravandi F, Konopleva M, Borthakur G, Daver N, Kanagal-Shammana R, Loghavi S, Qiao W, Huang X, Schneider H, Meyer M, Kantarjian H, Garcia-Manero G. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leuk Res 142:107518, 2024. e-Pub 2024. PMID: 38744144.
- Trentham-Dietz, A, Chapman, C, Jayasekera, J, Lowry, KP, Heckman-Stoddard, BM, Hampton, J, Caswell-Jin, JL, Gangnon, RE, Lu, Y, Huang, H, Stein, S, Sun, LP, Gil Quessep, EJ, Yang, Y, Lu, Y, Song, J, Munoz, D, Li, Y, Kurian, A, Kerlikowske, K, O'Meara, ES, Sprague, BL, Tosteson, AN, Feuer, EJ, Berry, D, Plevritis, SK, Huang, X, De Koning, HJ, Van Ravesteyn, NT, Lee, SJ, Alagoz, O, Schechter, CB, Stout, NK, Miglioretti, DL, Mandelblatt, J. Collaborative Modeling to Compare Different Breast Cancer Screening Strategies. Journal of American Medical Association 331(22):1947-1960, 2024. e-Pub 2024. PMID: 38687505.
- Zhou, S, Huang, X, Shen, C, Kantarjian, HM. Bayesian Learning of Personalized Longitudinal Biomarker Trajectory. Annals of Data Science 11(3):1031-1050, 2024. e-Pub 2024. PMID: 38855634.
- Urrutia, S, Bose, P, Alvarado, Y, Borthakur, G, Ravandi-Kashani, F, Daver, N, Pemmaraju, N, Jabbour, EJ, Takahashi, K, Kadia, TM, DiNardo, C, Kornblau, SM, Kanagal Shamanna, R, Huang, X, Bodden, K, Kantarjian, HM, Garcia-Manero, G. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML. Blood Neoplasia 1(2):100008, 2024. e-Pub 2024. PMID: 40454402.
- Chi S, Flowers CR, Li Z, Huang X, Wei P. MASH: Mediation Analysis of Survival Outcome and High-Dimensional Omics Mediators with Application to Complex Diseases. Annals of Applied Statistics 18(2):1360-1377, 2024. e-Pub 2024. PMID: 39328360.
- Wang Y, Flowers CR, Wang M, Huang X, Li Z. CASi: A framework for Cross-timepoint Analysis of Single-cell RNA sequencing data. Sci Rep 14(1):10633, 2024. e-Pub 2024. PMID: 38724550.
- Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol 42(13):JCO2301911, 2024. e-Pub 2024. PMID: 38277619.
- Valero V, Mouabbi J, Alonzo H, Pohlmann P, Lheme A, Hassan A, Murthy R, Huang X, Qiao W, Patel M, Rauch G, Checka C, Symmans WF, Hunt K, Tripathy D, Meric-Bernstam F. Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer. Cancer Research 84(9), 2024. e-Pub 2024.
- Gu J, Chery L, González GMN, Huff C, Strom S, Jones JA, Griffith DP, Canfield SE, Wang X, Huang X, Roberson P, Meng QH, Troncoso P, Ittmann M, Covinsky M, Scheurer M, Irizarry Ramirez M, Pettaway CA. A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening. Prostate 84(7):694-705, 2024. e-Pub 2024. PMID: 38477020.
- Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
- Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol 204(3):898-909, 2024. e-Pub 2024. PMID: 37946611.
- Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
- Short, NJ, Jabbour, EJ, Jain, N, Senapati, J, Nasr, L, Haddad, FG, Li, Z, Hsiao, YC, Yang, JJ, Pemmaraju, N, Ohanian, M, Wierda, WG, Montalban Bravo, G, Borthakur, G, Han, L, Xiao, L, Huang, X, Abramova, R, Zhao, M, Garris, R, Konopleva, M, Ravandi-Kashani, F, Kantarjian, HM. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Advances 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
- Caswell-Jin JL, Sun LP, Munoz D, Lu Y, Li Y, Huang H, Hampton JM, Song J, Jayasekera J, Schechter C, Alagoz O, Stout NK, Trentham-Dietz A, Lee SJ, Huang X, Mandelblatt JS, Berry DA, Kurian AW, Plevritis SK. Analysis of Breast Cancer Mortality in the US-1975 to 2019. JAMA 331(3):233-241, 2024. e-Pub 2024. PMID: 38227031.
- Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine/cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukemia: A phase 2 study. The Lancet Oncology 11(4):e276-e286, 2023. e-Pub 2023.
- Torralba AB, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, issa GC, Short N, Masarova L, Daver N, Kadia T, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Combination of oral decitabine/cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. The Lancet Haematology, 2023. e-Pub 2023.
- Koller P, Baran N, Harutyunyan K, Cavazos A, Mallampati S, Chin RL, Jiang Z, Sun X, Lee HH, Hsu JL, Williams P, Huang X, Curran MA, Hung MC, Konopleva M. PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity. J Immunother Cancer 11(10):e006619, 2023. e-Pub 2023. PMID: 37793852.
- Bazinet A, Kadia TM, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen JL, Patel KP, DiNardo CD, Daver NG, Alvarado Y, Haddad FG, Pierce SR, Nogueras Gonzalez GM, Maiti A, Sasaki K, Yilmaz M, Thompson PA, Wierda WG, Garcia-Manero G, Andreeff M, Jabbour EJ, Konopleva MY, Huang X, Kantarjian HM, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
- Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
- Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
- Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Combined Inhibition of BCL-2 and MCL-1 Overcomes BAX Deficiency-Mediated Resistance of TP53-mutant Acute Myeloid Leukemia to Individual BH3 Mimetics. Blood Cancer J 13(1):57, 2023. e-Pub 2023. PMID: 37088806.
- Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
- Jabbour, EJ, Short, NJ, Jain, N, Huang, X, Montalban Bravo, G, Banerjee, PP, Rezvani, K, Jiang, XL, Kim, KH, Kanagal Shamanna, R, Khoury, J, Patel, KP, Kadia, TM, Daver, N, Chien, KS, Alvarado, Y, Garcia-Manero, G, Issa, GC, Haddad, FG, Kwari, M, Thankachan, J, Delumpa, R, Macaron, W, Garris, R, Konopleva, M, Ravandi-Kashani, F, Kantarjian, HM. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Haematology 10(1):e24-e34, 2023. e-Pub 2023. PMID: 36402146.
- Xie C, Huang X, Li R, Pisters PW. A flexible-hazards cure model with application to patients with soft tissue sarcoma. Statistics in Medicine 41(29):5698-5714, 2022. e-Pub 2022. PMID: 36165535.
- Jabbour, EJ, Short, NJ, Jain, N, Thompson, PA, Kadia, TM, Ferrajoli, A, Huang, X, Yilmaz, M, Alvarado, Y, Patel, KP, Garcia-Manero, G, Macaron, W, Garris, R, Konopleva, M, Ravandi-Kashani, F, Kantarjian, HM. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia. The Lancet Haematology 9(12):e878-e885, 2022. e-Pub 2022. PMID: 36279879.
- Short, NJ, Fu, C, Berry, D, Walter, RB, Freeman, S, Hourigan, CS, Huang, X, Nogueras Gonzalez, G, Hwang, H, Qi, X, Kantarjian, HM, Zhou, S, Ravandi-Kashani, F. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia. Leukemia 36(12):2817-2826, 2022. e-Pub 2022. PMID: 36261575.
- Xie C, Li R, Huang X, Chihara D, Flowers CR. The Impact of Sequence of Therapy for Older Patients With Follicular Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 22(10):e938-e946, 2022. e-Pub 2022. PMID: 35871217.
- Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
- Wang Y, Flowers CR, Li Z, Huang X. CondiS Web App: Imputation of Censored Lifetimes for Machine Learning-Based Survival Analysis. Bioinformatics 38(17):4252-4254, 2022. e-Pub 2022. PMID: 35801895.
- Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006-4014, 2022. e-Pub 2022. PMID: 35533262.
- Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian K, Garcia-Manero G. A phase 1 study of azacitidine combined with venetoclax for myelodysplastic syndrome and chronic myelomonocytic leukaemia. Lancet Haematology 9(10):e756-e765, 2022. e-Pub 2022.
- Wang Y, Flowers CR, Li Z, Huang X. CondiS: A conditional survival distribution-based method for censored data imputation overcoming the hurdle in machine learning-based survival analysis. J Biomed Inform 131:104117, 2022. e-Pub 2022. PMID: 35690351.
- Wang, Y, Carter, BZ, Li, Z, Huang, X. Application of machine learning methods in clinical trials for precision medicine. Journal of the American Medical Informatics Association (JAMIA) Open 5(1):1-10, 2022. e-Pub 2022. PMID: 35178503.
- Wang ML, Wang ML, Jain P, Jain P, Zhao S, Zhao S, Lee HJ, Lee HJ, Nastoupil L, Nastoupil L, Fayad L, Fayad L, Ok CY, Ok CY, Kanagal-Shamanna R, Kanagal-Shamanna R, Hill HA, Hill HA, Yao Y, Yao Y, Liu Y, Liu Y, Hagemeister FB, Hagemeister FB, Westin J, Westin J, Fowler N, Fowler N, Samaniego F, Samaniego F, Steiner R, Steiner R, Nair R, Nair R, Iyer SP, Iyer SP, Chen W, Chen W, Oriabure O, Oriabure O, Moghrabi OB, Moghrabi OB, Navsaria L, Navsaria L, Che Y, Che Y, Li Y, Li Y, Avellaneda M, Avellaneda M, Badillo M, Badillo M, Feng L, Feng L, Huang X, Huang X, Nogueras Gonzalez GM, Nogueras Gonzalez GM, Xu G, Xu G, Wagner-Bartak N, Wagner-Bartak N, Thirumurthi S, Thirumurthi S, Santos D, Santos D, Tang G, Tang G, Lin P, Lin P, Wang SA, Wang SA, Jorgensen J, Jorgensen J, Yin CC, Yin CC, Li S, Li S, Patel KP, Patel KP, Vega F, Vega F, Medeiros LJ, Medeiros LJ, Flowers CR, Flowers CR, Wang L, Wang L. Ibrutinib-rituximab plus R-HCVAD as initial therapy in mantle cell lymphoma. Lancet Oncology 23(3):406-415, 2022. e-Pub 2022.
- Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II Study of Azacitidine with Pembrolizumab in Patients with Intermediate-1 or Higher-Risk Myelodysplastic Syndrome. Br J Haematol 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
- Zhang J, Ning J, Huang X, Li R. On the Time-varying Predictive Performance of Longitudinal Biomarkers: Measure and Estimation. Stat Med 40(23):5065-5077, 2021. e-Pub 2021. PMID: 34159633.
- Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
- Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An Effective Chemotherapy-Free Regimen of Ponatinib plus Venetoclax for Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Am J Hematol 96(7):e229-e232, 2021. e-Pub 2021. PMID: 33780038.
- Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
- Trentham-Dietz A, Alagoz O, Chapman C, Huang X, Jayasekera J, van Ravesteyn NT, Lee SJ, Schechter CB, Yeh JM, Plevritis SK, Mandelblatt JS. Reflecting On 20 Years of Breast Cancer Modeling In CISNET: Recommendations For Future Cancer Systems Modeling Efforts. PLOS Computational Biology 17(6):e1009020, 2021. e-Pub 2021.
- Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis 72(10):1755-1763, 2021. e-Pub 2021. PMID: 32236406.
- Shi B, Wei P, Huang X. Functional principal component based landmark analysis for the effects of longitudinal cholesterol profiles on the risk of coronary heart disease. Stat Med 40(3):650-667, 2021. e-Pub 2021. PMID: 33155338.
Review Articles
- Alagoz, O, Caswell-Jin, JL, De Koning, HJ, Huang, H, Huang, X, Lee, SJ, Li, Y, Plevritis, SK, Sarkar, S, Schechter, CB, Stout, NK, Trentham-Dietz, A, Van Ravesteyn, NT, Lowry, KP, Lee, SJ, Weedon-Fekjær, H, De Koning, HJ, Van Ravesteyn, NT, Heijnsdijk, EA, Quessep, EG, Groeneweg, R, Chootipongchaivat, S, Mandelblatt, JS, Chapman, C, Jayasekera, J, Berry, D, Song, J, Yang, Y, Caswell-Jin, JL, Kurian, A, Munoz, D, Sun, L, Gangnon, RE, Hampton, J, Lu, Y, Stein, S, Feuer, EJ, Heckman-Stoddard, BM, Kerlikowske, K, Miglioretti, DL, Sprague, BL, Tosteson, AN. Mathematical Modeling to Address Questions in Breast Cancer Screening. Journal of Breast Imaging 7(2):141-154, 2025. e-Pub 2025. PMID: 40036318.
Abstracts
- Short NJ, Kantarjian HM, Daver NG, Azevedo RS, Karrar O, DiNardo CD, Kadia TM, Yilmaz M, Maroun MM, Hachem MCR, Borthakur G, Issa GC, Shpall EJ, Popat UR, Huang X, Qiao W, Nasr LF, Macaron W, Abramova R, Garcia-Manero G, Konopleva M, Ravandi F. Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML. Blood Adv, 2026. e-Pub 2026. PMID: 42200455.
- Maiti A, Muftuoglu M, Ignatz-Hoover JJ, DiNardo CD, Ravandi F, Andreeff M, Xiao L, Huang X, Patel KP, Litten JB, Bourk E, Astrow S, Kantarjian HM, Tomlinson BK, Daver N, Wald D. Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial. 65th Annual Meeting of the American Society of Hematology, 2023. e-Pub 2023.
- Haddad FG, Jabbour E, Sasaki K, Nasr L, Huang X, Issa GC, Ravandi F, Garcia-Manero G, Kadia TM, Daver N, Valero YA, Nasnas C, Ohanian M, Short NJ, Masarova L, Zoghbi M, Nasnas PE, Montalban-Bravo G, Skinner J, Pierce S, Andreeff M, Kantarjian HM. Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML). Annual Meeting of the American Society of Hematology, 2023. e-Pub 2023.
- Haddad FG, Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Kadia TM, Daver N, Nasnas C, Mayor E, Nasnas PE, Deen W, Zoghbi M, Thankachan J, Loiselle C, Garris R, Ravandi F, Kantarjian HM. Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial. Annual Meeting of the American Society of Hematology, 2023. e-Pub 2023.
- Montalban-Bravo G, Short NJ, Chien KS, Valero YA, Daver N, Borthakur G, Swaminathan M, Maiti A, Hammond DE, Nogueras-Gonzalez G, Huang X, Schneider H, Shelly K, Kadia TM, Kantarjian HM, Garcia-Manero G. Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes. Annual Meeting of the American Society of Hematology, 2023. e-Pub 2023.
- Bataller A, Montalban-Bravo G, Bazinet A, Valero YA, Chien KS, Venugopal S, Ishizawa J, Hammond DE, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver N, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria. Annual Meeting of the American Society of Hematology, 2023. e-Pub 2023.
- Montalban-Bravo G, Jabbour E, Chien KS, Hammond DE, Short NJ, Ravandi F, Konopleva MY, Borthakur G, Daver N, Kanagal-Shamanna R, Qiao W, Huang X, Schneider H, Meyer MA, Kantarjian HM, Garcia-Manero G. Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms. Annual Meeting of the American Society of Hematology, 2023. e-Pub 2023.
- Haddad F, Jabbour E, Zoghbi M, Short N, Nasnas C, Nasr L, Macaron W, Jain N, Huang X, Montalban-Bravo G, Kadia T, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa G, Kwari M, Delumpa R, Mayor E, Deen W, Thankachan J, Loiselle C, Rivera J, Milton A, Waller L, Banks G, Garris R, Ravandi F, Kantarjian H. Ponatinib and blinatumomab in relapsed/refractory philadelphia-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase. The European Hematology Association, 2023. e-Pub 2023.
- Haddad F, Jabbour E, Nasnas C, Short N, Macaron W, Zoghbi M, Nasr L, Jain N, Almanza E, Sasaki K, Ravandi F, Kebriaei P, Huang X, Garcia-Manero G, Kadia T, Wang S, Jacob J, Garris R, O’brien S, Kantarjian H. Combination of mini-hyper-cvd and inotuzumab (ino) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (r/r) acute lymphoblastic leukemia. The European Hematology Association, 2023. e-Pub 2023.
- Short N, Jabbour E, Jain N, Huang X, Macaron W, Nasr L, Montalban-Bravo G, Kadia T, Daver N, Chien K, Alvarado Y, Issa G, Haddad F, Nasnas C, Zoghbi M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A chemotherapy-free combination of ponatinib and blinatumomab for patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia. The European Hematology Association, 2023. e-Pub 2023.
- Nasnas CC, Jabbour E, Haddad F, Short NJ, Macaron W, Zoghbi M, Nasr LF, Jain N, Almanza E, Sasaki K, Ravandi F, Kebriaei P, Huang X, Garcia-Manero G, Kadia TM, Wang SA, Jacob J, Garris R, O'Brien SM, Kantarjian HM. Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). American Society of Clinical Oncology, 2023. e-Pub 2023.
- Short NJ, Bachireddy P, Huang X, Hwang H, Leng X, Lee J, Nguyen D, Garcia-Manero G, Dinardo CD, Borthakur G, Kadia TM, Daver NG, Issa GC, Maiti A, Ravandi F. A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure. American Society of Clinical Oncology, 2023. e-Pub 2023.
Book Chapters
- Huang X, Qiao W, Xia F, Lin E, Zhu L, Ning J. Statistical Designs for Oncology Clinical Trials. In: The MD Anderson Manual of Medical Oncology. 4. McGraw Hill, 2022.
- Zhu Y, Li L, Huang X. On the Landmark Survival Model for Dynamic Prediction of Event Occurrence Using Longitudinal Data. In: New Frontiers in Biostatistics and Bioinformatics, 387-401, 2018.
- Huang X. Applied Biostatistics. In: The MD Anderson Manual of Medical Oncology. 3. McGraw Hill Education, 1021-1030, 2016.
Letters to the Editor
- Sasaki K, Kantarjian H, Rausch CR, Goulart H, Jain N, Huang X, Wierda WG, Kadia TM, Borthakur G, Issa GC, Alvarado Y, Pemmaraju N, Garris R, Ravandi F, Garcia-Manero G, Short NJ, Jabbour E. Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis. American Journal of Hematology 101, 2026.
- Akiyama, H, Nishida, Y, Chang, KH, Bedoy, AD, Muftuoglu, M, Ma, W, Basyal, M, Hirschi, Z, Honma, D, Tsutsumi, S, Wang, J, Zhang, W, Huang, X, Rampal, R, Oluwole, OO, Bixby, D, Daver, N, Andreeff, M. Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia. Blood cancer journal 15, 2025.
- Bouligny, IM, MontalbanBravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Bose, P, Pemmaraju, N, Kornblau, SM, Kadia, TM, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, KanagalShamanna, R, Hosing, C, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica 110: 1628-1633, 2025.
- Bouligny, IM, Montalban-Bravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, CD, Ravandi, F, Borthakur, G, Pemmaraju, N, Kadia, TM, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, Kanagal, R, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39: 524-528, 2025.
Patient Reviews
CV information above last modified August 25, 2026